Axsome Therapeutics
Logotype for Axsome Therapeutics Inc

Axsome Therapeutics (AXSM) investor relations material

Axsome Therapeutics UBS Global Biopharma Conference 2026 summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Axsome Therapeutics Inc
UBS Global Biopharma Conference 2026 summary16 Nov, 2026

Commercial performance

  • Q3 total net sales were $260M, a first-ever annualized run rate above $1B; AUVELITY generated $208M, up 53% YoY.

  • SUNOSI revenue was $48M, including an $8.5M milestone payment; SYMBRAVO revenue was ~$4M, with scripts continuing to grow.

  • AUVELITY MDD under-65 sales grew 33% YoY in Q3 versus 31% in Q2, and just over 10% sequentially; management expects durable long-term growth.

  • Management cited continued AUVELITY MDD growth in monotherapy and first- and second-line use, alongside positive prescriber feedback on AD agitation efficacy and tolerability.

AUVELITY launch and growth drivers

  • AUVELITY NBRxs grew >200% YoY, from 2,400/week on average in Q1 to 3,800 in October; management views NBRxs as a leading indicator for future TRx growth.

  • The field team expanded from ~270 reps at the start of the year to >650, including long-term care; management expects further growth-team investment to support uptake.

  • Using patients aged 65+ as an imperfect AD agitation proxy, NBRxs rose 260%, from ~1,000/month before April 2026 approval to 3,600/month; the measure includes MDD patients.

  • Patients aged 65+ represented 13.5% of Q3 AUVELITY scripts versus ~9.5%-10% in Q1-Q2; applying that share to sales implies ~$30M, not a direct indication breakout.

  • Sales-team expansion and the label expansion began showing initial impact within the expected one-to-two-quarter window; community reps entered the field in June.

  • AD agitation sampling uses a three-week titration pack versus three days for MDD; management is seeing sampled prescribers subsequently write scripts at a population level.

  • Management retains an $8B peak-sales opportunity for AUVELITY, roughly split 50/50 between AD agitation and MDD; Q4 gross-to-net could tick up slightly as mix evolves.

Solriamfetol and pipeline

  • ENGAGE, one of two studies needed to add binge eating disorder to the label, is expected to read out in 2027; a positive result would enable the second study to proceed.

  • Management cited potential sales opportunities of $500M-$1B in binge eating disorder and $1B-$3B in ADHD; two ADHD trial results are expected later in 2027.

  • Solriamfetol is also being studied in MDD with excessive daytime sleepiness and shift work disorder; the latter trial is enrolling.

  • AXS-20 is in tech transfer, with Phase III initiation planned for 2027; prior Phase II data were described as compelling, with potential differentiation in efficacy and tolerability.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Axsome Therapeutics earnings date

Logotype for Axsome Therapeutics Inc
Q4 202622 Feb, 2027
Axsome Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Axsome Therapeutics earnings date

Logotype for Axsome Therapeutics Inc
Q4 202622 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Find what matters

AI across all first-party IR material. Live calls, transcripts, slides, filings.
A cited source card from Adobe's CFO alongside a list of forward-looking statements

Trust every finding

50m+ first-party documents. Every output traceable to its source.

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more
An automation set to trigger on the first published earnings document for GE Aerospace

Event-triggered research

Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.
An automation scheduled to run weekly on Mondays at 09:00

Scheduled research

Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more
A live LVMH Q2 2026 earnings call playing in Quartr

Live earnings calls

Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.
A live transcript excerpt from LVMH's Chairman and CEO Bernard Arnault

Live transcripts

Speaker-by-speaker, in real time. Searchable across every live and historical call.

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Axsome Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. The company's portfolio includes product candidates designed to address conditions such as depression, migraines, and other neurological and psychiatric disorders. The company is headquartered in New York, New York, and its shares are listed on the NASDAQ.